- Home
- CORT
as 11-21-2024 11:33am EST
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 4.0B | IPO Year: | N/A |
| Target Price: | $75.25 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.26 | EPS Growth: | 57.97 |
| 52 Week Low/High: | $20.84 - $61.66 | Next Earning Date: | 10-30-2024 |
| Revenue: | $628,555,000 | Revenue Growth: | 39.67% |
| Revenue Growth (this year): | 46.29% | Revenue Growth (next year): | 17.09% |
Stock Insider Trading Activity of Corcept Therapeutics Incorporated (CORT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Swisher Daniel N JR | CORT | Director | Nov 11 '24 | Sell | $59.88 | 2,200 | $131,736.00 | 0 | |
| Guyer William | CORT | Chief Development Officer | Nov 1 '24 | Sell | $48.97 | 10,000 | $489,700.00 | 5,796 | |
| Guyer William | CORT | Chief Development Officer | Oct 1 '24 | Sell | $46.28 | 10,000 | $462,800.00 | 5,796 | |
| Robb Gary Charles | CORT | Chief Business Officer | Sep 27 '24 | Sell | $46.28 | 11,000 | $509,080.00 | 22,772 | |
| Guyer William | CORT | Chief Development Officer | Sep 3 '24 | Sell | $35.30 | 10,000 | $353,000.00 | 5,796 | |
| Robb Gary Charles | CORT | Chief Business Officer | Aug 26 '24 | Sell | $35.71 | 3,101 | $110,736.71 | 22,772 |
Latest Corcept Therapeutics Incorporated News
CORT Breaking Stock News: Dive into CORT Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Wall Street Analysts Think Corcept (CORT) Could Surge 37.91%: Read This Before Placing a Bet
Argus Research
9 days ago
CORT: Rating decreased to a HOLD
Zacks
10 days ago
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
Zacks
13 days ago
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
Zacks
13 days ago
5 Stocks With Recent Price Strength to Tap Wall Street Rally
Zacks
14 days ago
Catalyst Pharmaceuticals, Inc. (CPRX) Hit a 52 Week High, Can the Run Continue?
Zacks
15 days ago
Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?
Simply Wall St.
15 days ago
3 US Growth Stocks With Insider Ownership As High As 37%
Compare CORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CORT Corcept Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.